RU 486 approved in Britain; U.S. research still limited.
D000019:Abortifacient Agents; D000028:Abortion, Induced; D000569:Americas; D001695:Biology; D001943:Breast Neoplasms; D003257:Consumer Product Safety; D019049:Developed Countries; D004194:Disease; D004703:Endocrine System; D005060:Europe; D005193:Family Planning Services; D005602:France; D006727:Hormone Antagonists; D006728:Hormones; D007878:Legislation as Topic; D015735:Mifepristone; D009369:Neoplasms; D009656:North America; D010827:Physiology; D011453:Prostaglandins; D012537:Scandinavian and Nordic Countries; D006113:United Kingdom; D014481:United States
D000019:Abortifacient Agents; D006727:Hormone Antagonists; D006728:Hormones; D011453:Prostaglandins; D015735:Mifepristone
Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Breast Cancer; Cancer; Developed Countries; Diseases; Endocrine System; Europe; Family Planning; Fertility Control, Postconception; France; Hormone Antagonists; Hormones; Legislation; Mediterranean Countries; Neoplasms; North America; Northern America; Northern Europe; Physiology; Product Approval; Prostaglandins; Ru-486--therapeutic use; Scandinavia; United Kingdom; United States; Western Europe